The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.

The present invention relates to in vitro cultured senescent cells, such as epithelial cells, keratinocytes and/or fibroblasts as well as their use in the treatment of tissue regeneration, particularly for the treatment of wounds such as burns or ulcers or the treatment of inflammatory conditions. Optionally, products may be used in combination with further drugs including antimicrobial or antidiabetic agents.

Methods for treating a wound with a wound packing are discussed. While the wound packing can include any suitable component, in some cases, it includes a collection of multi-potent cells (e.g., cells from bone marrow, amniotic membrane tissue, amniotic fluid, stem cells, etc.), plasma (e.g., concentrated and/or platelet rich plasma), and collagen (e.g., native and/or organized reconstituted collagen). In some cases, the wound packing is gelled, coagulated, or otherwise hardened through the use of thrombin, calcium chloride, and/or another suitable additive. In some cases, the wound packing is shaped to substantially correspond to the wound's shape. While the wound packing can be used in any suitable manner, in some instances, it is applied to the wound, skin fragments are applied to the packing, the packing is secured to the wound, and/or the packing is covered with a protective barrier. Other implementations are also described.

A composition including long-term storable plasma-activated liquid (liquid plasma) as an active ingredient is disclosed. The long-term storable, atmospheric-pressure, plasma-activated liquid is prepared by dissolving a plasma generated using a low-temperature microplasma jet in a solution. The plasma-activated liquid not only exhibits a cancer cell killing effect at a level similar to gas-phase plasma according to a conventional art, but also maintains the cancer cell killing effect even when the plasma-activated liquid is stored in a freezer or in a cold chamber for 6 months, and thus is suitable for long-term storage. The plasma-activated liquid may be effectively used in the biopharmaceutical field, for example for a skin regeneration, wound-healing of dermal cells, and/or treating a cancer.

An immune-modulating biomaterial comprising a hydrogel scaffold coupled to D-amino acid containing peptides having unexpected properties in vivo is described. For example, certain inflammatory reactions in vivo are significantly increased around the D-peptide containing particles of hydrogel scaffold as compared to particles that contain both L and D peptides or L peptides alone. In addition, these D-peptide compositions are further observed to enhance wound healing and improve the tensile strength of healed tissues. For these and other reasons, the D-amino acid hydrogel materials disclosed herein are useful in a number of methodologies that seek to modulate the immune response and/or wound healing.

Methods and systems for stiffening of tissue are presented to allow improved processing. Solutions including an acid or a base can be contacted with tissue to stiffen one or more components of the tissue. The resulting stiffened tissue can be used in the creation of wound treatment devices.

A formulation of a discrete liquid patch for the treatment of cold sores or viral lesions, including a combination of the adhesive layer and an active compound/ingredient such as antiviral agents, and/or amino acids, and/or minerals/vitamins. The adhesive layer of the discrete patch is substantially free of hydrocolloid particles. The adhesive layer does not include any backing layer to maintain the compliance of the patch with a thickness ranging from 5 microns to 1,300 microns. Wherein, the discrete patch of the invention is configured to apply to a viral lesion to maintain in contact therewith for a time effective to substantially complete re-epithelialization of the lesion.

Device, method and assembly for wound treatment. Specifically a wound dressing device; an assembly, e.g. a kit-of-parts, including the device as a component; and method of wound dressing and use wherein the device is a key component. The device includes a cavity defined by concave walls surrounded by lips for attachment to skin in fluid tight manner and a closure removably fixed to the lips and sealing the cavity. The assembly also includes, as another component a device for introducing blood into the cavity after it is fixed over a wound to permit the blood to clot over the wound within the cavity. In use, the clotting mold device is fixed on top of a wound, and blood is introduced into the mold space to permit the blood to clot within the mold space to form a blood clot over the wound.

The invention relates to plasmids capable of expressing a protein targeting immune cells when transformed into a lactic acid bacterial cell, wherein the protein is chosen from the group consisting of murine and human CXCL12 1; CXCL17 and Ym1. The invention further relates to lactic acid bacteria transformed with a said plasmid, as well as the use of said lactic acid bacteria for wound healing in humans and animals.